



**Universiteit
Leiden**
The Netherlands

Towards personalized treatment for high risk endometrial cancer

Post, C.C.B.

Citation

Post, C. C. B. (2023, June 13). *Towards personalized treatment for high risk endometrial cancer*. Retrieved from <https://hdl.handle.net/1887/3620169>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3620169>

Note: To cite this publication please use the final published version (if applicable).

Towards personalized treatment for high risk endometrial cancer

Cathalijne C.B. Post

Towards personalized treatment for high risk endometrial cancer

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 13 juni 2023
klokke 15.00 uur

door

Cathalijne Catharina Bastiana Post
geboren te Nieuwegein
in 1994

Towards personalized treatment for high risk endometrial cancer

PhD thesis, University of Leiden, Leiden, The Netherlands

ISBN: 978-94-6469-322-5

Cover design and layout: Cathalijne C.B. Post

Printing: Proefschriftmaken.nl

The research described in this thesis was financially supported by unrestricted grants from the Dutch Cancer Society (UL2012-5719, CKTO90-01, CKTO 2001-04 en UL2006-4168/CKTO 2006-04) and AstraZeneca.

© **Cathalijne C.B. Post, 2023**. The Netherlands. All rights reserved. No part of this thesis may be reproduced, stored or transmitted in any form or by any means without prior permission of the author or the copyright-owning journals for previous published papers.

Promotor:	Prof. dr. C.L. Creutzberg
Co-promotors:	Dr. J.R. Kroep Dr. T. Bosse
Promotiecomissie:	Prof. dr. V.H.B.T.M Smit Prof. dr. A.J. Gelderblom Dr. A.M. Westermann, Amsterdam UMC Prof. dr. L.V. van de Poll-Franse, Tilburg University Prof. dr. C.J. van Asperen

TABLE OF CONTENTS

Chapter 1	General introduction	7
Chapter 2	Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high risk endometrial cancer in the randomized PORTEC-3 trial	23
Chapter 3	Patients' and clinicians' preferences in adjuvant treatment for high risk endometrial cancer: implications for shared decision making	63
Chapter 4	Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in endometrial cancer	85
Chapter 5	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer	113
Chapter 6	Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase 2 DOMEK trial)	135
Chapter 7	General discussion and future perspectives	157
Appendices	Nederlandse samenvatting	184
	List of publications and conference abstracts	190
	Curriculum vitae	193
	Dankwoord	194